Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
NRx Pharmaceuticals, Inc. (NRXP) - free report >>
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NRx Pharmaceuticals, Inc. (NRXP) - free report >>
Image: Bigstock
Best Momentum Stocks to Buy for December 30th
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, December 30th:
CoreCard Corporation (CCRD - Free Report) : This technology solutions and processing services company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 7% over the last 60 days.
CoreCard Corporation Price and Consensus
CoreCard Corporation price-consensus-chart | CoreCard Corporation Quote
CoreCard’s shares gained 44.9% over the last three months compared with the S&P 500’s advance of 5.3%. The company possesses a Momentum Score of A.
CoreCard Corporation Price
CoreCard Corporation price | CoreCard Corporation Quote
Entrada Therapeutics, Inc. (TRDA - Free Report) : This clinical-stage biotechnology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 64.7% over the last 60 days.
Entrada Therapeutics, Inc. Price and Consensus
Entrada Therapeutics, Inc. price-consensus-chart | Entrada Therapeutics, Inc. Quote
Entrada’s shares gained 8.8% over the last three months compared with the S&P 500’s advance of 5.3%. The company possesses a Momentum Score of A.
Entrada Therapeutics, Inc. Price
Entrada Therapeutics, Inc. price | Entrada Therapeutics, Inc. Quote
NRx Pharmaceuticals, Inc. (NRXP - Free Report) : This clinical-stage biotechnology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 46.2% over the last 60 days.
NRx Pharmaceuticals, Inc. Price and Consensus
NRx Pharmaceuticals, Inc. price-consensus-chart | NRx Pharmaceuticals, Inc. Quote
NRx’s shares gained 11.8% over the past month compared with the S&P 500’s decline of 0.7%. The company possesses a Momentum Score of A.
NRx Pharmaceuticals, Inc. Price
NRx Pharmaceuticals, Inc. price | NRx Pharmaceuticals, Inc. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.